Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 7/2018

Open Access 01-07-2018 | Correspondence

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.

Author: Cynthia Feng

Published in: Digestive Diseases and Sciences | Issue 7/2018

Login to get access

Excerpt

To the Editor, …
Literature
1.
Quigley G, et al. Occurrence of jaundice following simultaneous ursodeoxycholic acid cessation and obeticholic acid initiation. Dig Dis Sci. 2018;63:529–532.CrossRefPubMed
2.
OCALIVA (obeticholic acid) [package insert]. Intercept Pharmaceuticals, Inc., New York, NY; 2018.
3.
Nevens F, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.CrossRefPubMed
4.
Quigley G, Al Ani M, Nadir A. Occurrence of jaundice following simultaneous ursodeoxycholic acid cessation and obeticholic acid initiation. Dig Dis Sci. 2018;63:529–532.CrossRefPubMed
5.
6.
Kowdley KV, Jones D, Luketic V, The OCA PBC Study Group. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. Journal of Hepatology. 2011;2011:S13.CrossRef
7.
Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751–761. (e758).CrossRefPubMed
8.
La Pietra L, Calligaris L, Molendini L, Quattrin R, Brusaferro S. Medical errors and clinical risk management: state of the art. Acta otorhinolaryngologica Italica. 2005;25:339–346.PubMedPubMedCentral
Metadata
Title
Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
Author
Cynthia Feng
Publication date
01-07-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5083-7

Other articles of this Issue 7/2018

Digestive Diseases and Sciences 7/2018 Go to the issue

Original Article

Advanced Age Does Not Negatively Impact Health-Related Quality of Life in Inflammatory Bowel Disease

Original Article

Natural Language Processing Accurately Calculates Adenoma and Sessile Serrated Polyp Detection Rates

Review

Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites

Publisher Correction

Correction to: Hypervigilance to a Gluten-Free Diet and Decreased Quality of Life in Teenagers and Adults with Celiac Disease

Original Article

Pyruvate Kinase Isozyme M2 Plays a Critical Role in the Interactions Between Pancreatic Stellate Cells and Cancer Cells

Original Article

Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits